Global Endocrine Therapy Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024

  • receipt Report ID : 180957
  • calendar_today Published On: Jul, 2019
  • file_copy Pages: 135
  • list Pharmaceuticals and Healthcare

Scope of the Report:

The global Endocrine Therapy Drugs for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Endocrine Therapy Drugs for Breast Cancer.

Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.

This report studies the Endocrine Therapy Drugs for Breast Cancer market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Endocrine Therapy Drugs for Breast Cancer market by product type and applications/end industries.

Market Segment by Companies, this report covers

Teva

Amneal Pharms

AstraZeneca

Novartis

Intas Pharmaceuticals

Chemo

Accure Labs

Natco

Zydus Pharmaceuticals

Sanofi

Pfizer

Mylan 

Wockhardt

Cipla

Actiza Pharmaceutical

Hikma Pharmaceuticals

Shanghai Forward Technology

Bayer

Liaoning Kangtai Pharmaceutical

Fu 'an Pharmaceutical Group

Apotex

Taro

Sun Phamaceutical

Intas Pharmaceuticals

Chemo

Accure Labs

Sun Pharmaceutical

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Tamoxifen

Anastrozole

Exemestane

Letrozole

Goserelin

Fulvestrant

Market Segment by Applications, can be divided into

Hospital

Clinic

Drug Center

Other

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Endocrine Therapy Drugs for Breast Cancer Market Overview

1.1 Product Overview and Scope of Endocrine Therapy Drugs for Breast Cancer

1.2 Classification of Endocrine Therapy Drugs for Breast Cancer by Types

1.2.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue Comparison by Types (2019-2024)

1.2.2 Global Endocrine Therapy Drugs for Breast Cancer Revenue Market Share by Types in 2018

1.2.3 Tamoxifen

1.2.4 Anastrozole

1.2.5 Exemestane

1.2.6 Letrozole

1.2.7 Goserelin

1.2.8 Fulvestrant

1.3 Global Endocrine Therapy Drugs for Breast Cancer Market by Application

1.3.1 Global Endocrine Therapy Drugs for Breast Cancer Market Size and Market Share Comparison by Applications (2014-2024)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Drug Center

1.3.5 Other

1.4 Global Endocrine Therapy Drugs for Breast Cancer Market by Regions

1.4.1 Global Endocrine Therapy Drugs for Breast Cancer Market Size (Million USD) Comparison by Regions (2014-2024)

1.4.1 North America (USA, Canada and Mexico) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)

1.4.4 South America (Brazil, Argentina, Colombia) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)

1.5 Global Market Size of Endocrine Therapy Drugs for Breast Cancer (2014-2024)

2 Manufacturers Profiles

2.1 Teva

2.1.1 Business Overview

2.1.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Teva Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.2 Amneal Pharms

2.2.1 Business Overview

2.2.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Amneal Pharms Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.3 AstraZeneca

2.3.1 Business Overview

2.3.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 AstraZeneca Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.4 Novartis

2.4.1 Business Overview

2.4.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Novartis Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.5 Intas Pharmaceuticals

2.5.1 Business Overview

2.5.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Intas Pharmaceuticals Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.6 Chemo

2.6.1 Business Overview

2.6.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Chemo Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.7 Accure Labs

2.7.1 Business Overview

2.7.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Accure Labs Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.8 Natco

2.8.1 Business Overview

2.8.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Natco Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.9 Zydus Pharmaceuticals

2.9.1 Business Overview

2.9.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Zydus Pharmaceuticals Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.10 Sanofi

2.10.1 Business Overview

2.10.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Sanofi Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.11 Pfizer

2.11.1 Business Overview

2.11.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Pfizer Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.12 Mylan 

2.12.1 Business Overview

2.12.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.12.2.1 Product A

2.12.2.2 Product B

2.12.3 Mylan  Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.13 Wockhardt

2.13.1 Business Overview

2.13.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.13.2.1 Product A

2.13.2.2 Product B

2.13.3 Wockhardt Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.14 Cipla

2.14.1 Business Overview

2.14.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.14.2.1 Product A

2.14.2.2 Product B

2.14.3 Cipla Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.15 Actiza Pharmaceutical

2.15.1 Business Overview

2.15.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.15.2.1 Product A

2.15.2.2 Product B

2.15.3 Actiza Pharmaceutical Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.16 Hikma Pharmaceuticals

2.16.1 Business Overview

2.16.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.16.2.1 Product A

2.16.2.2 Product B

2.16.3 Hikma Pharmaceuticals Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.17 Shanghai Forward Technology

2.17.1 Business Overview

2.17.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.17.2.1 Product A

2.17.2.2 Product B

2.17.3 Shanghai Forward Technology Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.18 Bayer

2.18.1 Business Overview

2.18.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.18.2.1 Product A

2.18.2.2 Product B

2.18.3 Bayer Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.19 Liaoning Kangtai Pharmaceutical

2.19.1 Business Overview

2.19.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.19.2.1 Product A

2.19.2.2 Product B

2.19.3 Liaoning Kangtai Pharmaceutical Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.20 Fu 'an Pharmaceutical Group

2.20.1 Business Overview

2.20.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.20.2.1 Product A

2.20.2.2 Product B

2.20.3 Fu 'an Pharmaceutical Group Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.21 Apotex

2.21.1 Business Overview

2.2.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.21.2.1 Product A

2.21.2.2 Product B

2.21.3 Apotex Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.22 Taro

2.22.1 Business Overview

2.22.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.22.2.1 Product A

2.22.2.2 Product B

2.22.3 Taro Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.23 Sun Phamaceutical

2.23.1 Business Overview

2.23.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.23.2.1 Product A

2.23.2.2 Product B

2.23.3 Sun Phamaceutical Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.24 Intas Pharmaceuticals

2.24.1 Business Overview

2.24.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.24.2.1 Product A

2.24.2.2 Product B

2.24.3 Intas Pharmaceuticals Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.25 Chemo

2.25.1 Business Overview

2.25.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.25.2.1 Product A

2.25.2.2 Product B

2.25.3 Chemo Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.26 Accure Labs

2.26.1 Business Overview

2.26.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.26.2.1 Product A

2.26.2.2 Product B

2.26.3 Accure Labs Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

2.27 Sun Pharmaceutical

2.27.1 Business Overview

2.27.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications

2.27.2.1 Product A

2.27.2.2 Product B

2.27.3 Sun Pharmaceutical Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

3 Global Endocrine Therapy Drugs for Breast Cancer Market Competition, by Players

3.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue and Share by Players (2014-2019)

3.2 Market Concentration Rate

3.2.1 Top 5 Endocrine Therapy Drugs for Breast Cancer Players Market Share

3.2.2 Top 10 Endocrine Therapy Drugs for Breast Cancer Players Market Share

3.3 Market Competition Trend

4 Global Endocrine Therapy Drugs for Breast Cancer Market Size by Regions

4.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue and Market Share by Regions

4.2 North America Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

4.3 Europe Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

4.4 Asia-Pacific Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

4.5 South America Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

4.6 Middle East and Africa Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

5 North America Endocrine Therapy Drugs for Breast Cancer Revenue by Countries

5.1 North America Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)

5.2 USA Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

5.3 Canada Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

5.4 Mexico Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

6 Europe Endocrine Therapy Drugs for Breast Cancer Revenue by Countries

6.1 Europe Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)

6.2 Germany Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

6.3 UK Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

6.4 France Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

6.5 Russia Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

6.6 Italy Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Endocrine Therapy Drugs for Breast Cancer Revenue by Countries

7.1 Asia-Pacific Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)

7.2 China Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

7.3 Japan Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

7.4 Korea Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

7.5 India Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

7.6 Southeast Asia Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

8 South America Endocrine Therapy Drugs for Breast Cancer Revenue by Countries

8.1 South America Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)

8.2 Brazil Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

8.3 Argentina Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

8.4 Colombia Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Endocrine Therapy Drugs for Breast Cancer by Countries

9.1 Middle East and Africa Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)

9.2 Saudi Arabia Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

9.3 UAE Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

9.4 Egypt Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

9.5 Nigeria Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

9.6 South Africa Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

10 Global Endocrine Therapy Drugs for Breast Cancer Market Segment by Type

10.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue and Market Share by Type (2014-2019)

10.2 Global Endocrine Therapy Drugs for Breast Cancer Market Forecast by Type (2019-2024)

10.3 Tamoxifen Revenue Growth Rate (2014-2024)

10.4 Anastrozole Revenue Growth Rate (2014-2024)

10.5 Exemestane Revenue Growth Rate (2014-2024)

10.6 Letrozole Revenue Growth Rate (2014-2024)

10.7 Goserelin Revenue Growth Rate (2014-2024)

10.8 Fulvestrant Revenue Growth Rate (2014-2024)

11 Global Endocrine Therapy Drugs for Breast Cancer Market Segment by Application

11.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue Market Share by Application (2014-2019)

11.2 Endocrine Therapy Drugs for Breast Cancer Market Forecast by Application (2019-2024)

11.3 Hospital Revenue Growth (2014-2019)

11.4 Clinic Revenue Growth (2014-2019)

11.5 Drug Center Revenue Growth (2014-2019)

11.6 Other Revenue Growth (2014-2019)

12 Global Endocrine Therapy Drugs for Breast Cancer Market Size Forecast (2019-2024)

12.1 Global Endocrine Therapy Drugs for Breast Cancer Market Size Forecast (2019-2024)

12.2 Global Endocrine Therapy Drugs for Breast Cancer Market Forecast by Regions (2019-2024)

12.3 North America Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)

12.4 Europe Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)

12.5 Asia-Pacific Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)

12.6 South America Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)

12.7 Middle East and Africa Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Endocrine Therapy Drugs for Breast Cancer Picture

Table Product Specifications of Endocrine Therapy Drugs for Breast Cancer

Table Global Endocrine Therapy Drugs for

Please fill the form below, to recieve the report sample


+1